Status:

UNKNOWN

Severe Asthma Exacerbations and Mepolizumab Treatment

Lead Sponsor:

Università degli Studi di Ferrara

Collaborating Sponsors:

GlaxoSmithKline

Conditions:

Severe Asthma

Eligibility:

All Genders

18+ years

Brief Summary

This is a hypothesis-generating project to investigate a) infective etiology and b) inflammatory profile of the exacerbations of asthma in severe asthmatic patients treated with the humanized monoclon...

Detailed Description

Longitudinal, observational study to evaluate the infective etiology and the inflammatory profile of asthma exacerbations in severe asthmatic patients treated (as part of routine medical care) with th...

Eligibility Criteria

Inclusion

  • The cohort of patients included in the study will consist of severe asthmatic patients receiving Mepolizumab as part of routine medical care, i.e. eligible for Mepolizumab treatment according to the Italian Medicine Agency (AIFA; Agenzia Italiana del Farmaco). The patients will receive Mepolizumab treatment irrespective of the enrollment in the study but because of the clinical indication.
  • Inclusion criteria:
  • severe asthmatic patients according to GINA document (Step 4 and 5 GINA)
  • blood eosinophilic count above 300 cells/mcl at least once in the previous year and ≥150 cells/mcl in the absence of systemic corticosteroid treatment before biological treatment initiation.
  • In addition, one of the following conditions will be required: 1) ≥2 exacerbations in the previous year despite appropriate inhaled treatments or 2) the need for systemic corticosteroids on top of inhaled treatment for at least 6 months in the previous year.
  • Exclusion criteria:
  • COPD
  • Active smoking
  • Chronic interstitial lung diseases
  • Systemic corticosteroid/immunosuppressive treatments for concomitant conditions other than asthma

Exclusion

    Key Trial Info

    Start Date :

    September 21 2021

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ESTIMATED

    End Date :

    December 1 2023

    Estimated Enrollment :

    70 Patients enrolled

    Trial Details

    Trial ID

    NCT04914078

    Start Date

    September 21 2021

    End Date

    December 1 2023

    Last Update

    May 18 2022

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Azienda Ospedaliero Universitaria Ferrara

    Ferrara, Italy, 44124